Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Glucophage

    - PMLiVE

    Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

    Cladribine capsules could become the first ever oral treatment for gMG

    - PMLiVE

    Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition

    SpringWorks’ Gomekli was approved by the FDA earlier this year to treat patients with NF1

    - PMLiVE

    Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

    The neurological disorder affects more than 150,000 people in the UK

    - PMLiVE

    Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type

    The companies entered into a licensing agreement for the candidate in December last year

    - PMLiVE

    Merck KGaA signs definitive agreement to acquire Mirus Bio in deal worth $600m

    The deal aims to advance Merck’s viral vector manufacturing of cell and gene therapies

    - PMLiVE

    Merck KGaA and Caris enter oncology partnership worth over $1.4bn

    The alliance is aimed at accelerating the development of ADCs for cancer patients

    - PMLiVE

    Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m

    The collaboration will utilise C4T’s TORPEDO platform to target and degrade disease-associated proteins

    - PMLiVE

    Merck gains rights to Inspirna’s colorectal cancer drug for $45m upfront

    Ompenaclid is in phase 2 development to treat advanced or metastatic colorectal cancer

    - PMLiVE

    Merck gains rights to Abbisko’s pimicotinib in deal worth over $70m

    The candidate is currently in late-stage development for tenosynovial giant cell tumour

    - PMLiVE

    New study finds dose of subcutaneous cladribine could predict MS relapse risk

    The disease affects approximately 130,000 people in the UK and currently has no cure

    - PMLiVE

    Merck KGaA and Hengrui Pharmaceuticals announce oncology partnership worth over €1.4bn

    The deal includes a next-generation PARP1 inhibitor and an antibody drug conjugate

    - PMLiVE

    Merck KGaA’s MS drug put on partial clinical hold by FDA

    Laboratory results suggested there were two cases of drug-induced liver injury during the phase 3 studies

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links